Related Experiment Video
Updated: May 11, 2026
11:20
Site-Directed Immobilization of Bone Morphogenetic Protein 2 to Solid Surfaces by Click Chemistry
Published on: March 29, 2018
Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2
Sheldon X Lu1, Tiago Fiorini, Jaebum Lee
1Laboratory for Applied Periodontal & Craniofacial Regeneration LAPCR, Georgia Regents University College of Dental Medicine, Augusta, GA, USA.
Journal of Clinical Periodontology
|May 1, 2013
Summary
The compression resistant matrix (CRM) loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2) significantly enhanced bone formation and density compared to the absorbable collagen sponge (ACS) carrier. Further studies are needed to assess bone maturation and seroma resolution.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Skeletal Biology
Background:
- Recombinant human bone morphogenetic protein-2 (rhBMP-2) shows therapeutic potential for bone regeneration.
- Current carriers like absorbable collagen sponge (ACS) lack structural integrity for certain bone grafting applications.
- A novel compression resistant matrix (CRM) was developed to improve rhBMP-2 delivery for onlay bone grafting.
Purpose of the Study:
- To evaluate and compare local bone formation and osseointegration using rhBMP-2 delivered via a CRM versus an ACS.
- To assess the efficacy of a CRM as a carrier for rhBMP-2 in critical-size bone defects.
Main Methods:
- Five dogs with critical-size supraalveolar peri-implant defects received rhBMP-2 (0.8 mg) loaded onto either ACS or CRM.
- Defects were closed submerged for primary intention healing.
- Histologic and histometric evaluations were performed at 8 weeks post-implantation.
Main Results:
- rhBMP-2/CRM significantly increased bone area and density compared to rhBMP-2/ACS.
- No significant differences were found in new bone height or osseointegration between the groups.
- Both groups exhibited immature bone formation, seroma formation, and residual ceramic granules in the CRM group.
Conclusions:
- The CRM carrier supports significant bone formation with clinically relevant geometry when combined with rhBMP-2.
- Longer observation periods and dose adjustments are recommended to evaluate bone maturation, ceramic biodegradation, and seroma resolution.
